Kenvue Inc. (NYSE:KVUE) Declares Quarterly Dividend of $0.20

Kenvue Inc. (NYSE:KVUE) declared a quarterly dividend on Thursday, April 25th, Zacks reports. Stockholders of record on Wednesday, May 8th will be paid a dividend of 0.20 per share on Wednesday, May 22nd. This represents a $0.80 annualized dividend and a dividend yield of 4.17%. The ex-dividend date is Tuesday, May 7th.

Kenvue has a payout ratio of 65.0% meaning its dividend is sufficiently covered by earnings. Research analysts expect Kenvue to earn $1.25 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 64.0%.

Kenvue Stock Performance

Shares of NYSE:KVUE opened at $19.20 on Monday. The stock’s 50-day moving average is $19.82 and its 200 day moving average is $20.12. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. Kenvue has a 1 year low of $17.82 and a 1 year high of $27.80.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The business had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.78 billion. The firm’s revenue was down 2.7% on a year-over-year basis. On average, analysts anticipate that Kenvue will post 1.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on KVUE. JPMorgan Chase & Co. dropped their price objective on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. Royal Bank of Canada reduced their price objective on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Friday, February 9th. William Blair started coverage on Kenvue in a report on Wednesday, April 3rd. They issued a “market perform” rating on the stock. The Goldman Sachs Group initiated coverage on Kenvue in a report on Friday, March 1st. They set a “neutral” rating and a $20.00 price target for the company. Finally, Sanford C. Bernstein initiated coverage on shares of Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target on the stock. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $24.85.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.